biotech

Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.

Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.

Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.

AI-powered labs are expanding total experiment volume, pressuring commodity labware suppliers while strengthening the market position of scarce reagents and specialized inputs.